stoxline Quote Chart Rank Option Currency Glossary
  
Soleno Therapeutics, Inc. (SLNO)
29.83  0.07 (0.24%)    12-01 16:00
Open: 29.16
High: 30.42
Volume: 224,606
  
Pre. Close: 29.76
Low: 29.16
Market Cap: 910(M)
Technical analysis
2023-12-01 4:22:42 PM
Short term     
Mid term     
Targets 6-month :  35.53 1-year :  41.49
Resists First :  30.42 Second :  35.53
Pivot price 26.36
Supports First :  24.78 Second :  21.29
MAs MA(5) :  28.75 MA(20) :  25.44
MA(100) :  14.39 MA(250) :  7.61
MACD MACD :  1.9 Signal :  1.6
%K %D K(14,3) :  94.4 D(3) :  89.6
RSI RSI(14): 72.1
52-week High :  30.42 Low :  0.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SLNO ] has closed below upper band by 19.2%. Bollinger Bands are 50.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 30.47 - 30.59 30.59 - 30.72
Low: 28.87 - 28.99 28.99 - 29.12
Close: 29.62 - 29.84 29.84 - 30.07
Company Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Headline News

Fri, 01 Dec 2023
Insider Sell Alert: CFO James Mackaness Sells 8,081 Shares of ... - Yahoo Finance

Wed, 22 Nov 2023
Billionaire Seth Klarman's Biotech Stock Picks - Yahoo Finance

Thu, 09 Nov 2023
This Soleno Therapeutics Insider Reduced Their Stake By 92% - Simply Wall St

Tue, 07 Nov 2023
Soleno Therapeutics Provides Corporate Update and Reports Third ... - Yahoo Finance

Wed, 01 Nov 2023
Top Stocks for November 2023 - Investopedia

Mon, 02 Oct 2023
Soleno Therapeutics Announces Closing of Underwritten Public ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 31 (M)
Shares Float 16 (M)
Held by Insiders 10.9 (%)
Held by Institutions 66.3 (%)
Shares Short 682 (K)
Shares Short P.Month 1,570 (K)
Stock Financials
EPS -3.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.5
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -42 %
Return on Equity (ttm) -172.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.99
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow 8 (M)
Stock Valuations
PE Ratio -9.3
PEG Ratio -0.8
Price to Book value 19.88
Price to Sales 0
Price to Cash Flow -38.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android